Диссертация (1141239), страница 28
Текст из файла (страница 28)
ClinCancer Res 2009;15:3305-3314.100. Pennathur A, Landreneau RJ, Luketich JD. Surgical aspects of the patientwith high-grade dysplasia. Semin Thorac Cardiovasc Surg 2005; 17: 326–32.166101. Pennathur A., Gibson M.K., Jobe B.A., Luketich J.D. Oesophagealcarcinoma. Lancet. 2013; 381: 400–412.102. Pohl H, Welch HG. The role of overdiagnosis and reclassification in themarked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst2005;97:142-146.103. Provenzale D., Kemp J.A., Arora S., Wong J.B. A guide for surveillance ofpatient with Barrett's esophagus // Am. J.
Gastroenterol. - 1994. - Vol. 89. — P.670-680.104. Reid B. J., X. Li, P. C. Galipeau, and T. L. Vaughan, ―Barrett‘s oesophagusand oesophageal adenocarcinoma: time for a new synthesis,‖ Nature ReviewsCancer, vol. 10,no. 2, pp.87–101, 2010.105. Reid B.J., Weinstein W.M., Lewin K.J., Haggitt R.C., VanDeventer G.,DenBesten L., Rubin C.E. Endoscopic biopsy can detect high-grade dysplasia orearly adenocarcinoma in Barrett‘s esophagus without grossly recognizableneoplastic lesions. Gastroenterology.
1988.106. Riddell R. H. and R.D.Odze, ―Definition of barrett‘s sophagus:time for arethinkis intestinal metaplasia dead,‖ AmericanJournal of Gastroenterology, vol.104, no. 10, pp. 2588–2594,2009.107. RobertsonEV,JankowskiJA.Geneticsofgastroesophagealcancer:paradigms, paradoxes, and prognostic utility. Am J Gastroenterol2008;103:443–9.108. Sampliner RE. Multipolar electrocoagulation. // Gastrointest Endosc Clin NAm.
2003 Jul;13(3):449-55.109. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation inBarrett's esophagus with dysplasia. N Engl J Med. 2009; 360:2277–2288.110. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow bandimaging endoscopy system in patients with Barrett's esophagus. GastrointestEndosc 2006;64:167-175.167111. Shebrain Saad, MD; Huseyin Sinan, MD; Brant K.
Oelschlager, MD,Laparoscopic Repeated Nissen Fundoplication for Recurrent GastroesophagealReflux Disease, Medscape Gastroenterology, October 01, 2009.112. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophagealadenocarcinoma and mortality in patients with Barrett's esophagus: a systematicreview and meta-analysis. ClinGastroenterolHepatol 2010;8:235-244.113. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk ofoesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematicreview and meta-analysis. Gut 2014;63:1229e37.114.
Skinner D.B., Walther B.C., Riddell R.H., Schmidt H., Iascone C.,DeMeester T.R. Barrett‘s esophagus: comparison of benign and malignant cases.AnnSurg. 1983.115. Smith E., De Young N.J., Pavey S.J., Hayward N.K., NancarrowD.J.,Whiteman D.C., et al. Similarity of aberrant DNA methylation in Barrett'sesophagus and esophageal adenocarcinoma.
Mol. Cancer. 2008; 7: 75.116. Smith KJ, O'Brien SM, Smithers BM, etal. Interactions among smoking,obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer EpidemiolBiomarkers Prev 2005.117. Sobin L. H., M. K. Gospodarowicz, and C. Wittekind, TNM Classification ofmalignant Tumours, vol. 7, 7th edition, 2010.118. Somerville M., R. Garside, M. Pitt, and K. Stein, ―Surveillance of Barrett‘soesophagus: is it worthwhile?‖ European Journal of Cancer, vol. 44, no. 4, pp.588–599, 2008.119. Spechler S.J. et.
al. American Gastroenterological Association TechnicalReview on ManagementofBarrett'esophagus,Gastroenterology.2011 March;140(3).120. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. AmericanGastroenterological Association medical position statement on the management ofBarrett‘s esophagus. Gastroenterology 2011; 140: 1084-1091.121. SpechlerSJ,SouzaRF.Barrett'soesophagus.NEnglJMed2014;371:836e45.168122. Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR. Earlyesophageal cancer: pattern of lymphatic spread and prognostic factors for longterm survival after surgical resection. Ann Surg 2005.123.
Streppel MM, Lata S, Delabastide M, Montgomery EA, Wang JS, Canto MI,et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as atumor-suppressor gene in Barrett's esophagus. Oncogene. 2013 Jan 14.124. Stuart Jon Spechler, M.D., Rebecca C. Fitzgerald, M.D., Ganapathy A.Prasad, M.D., M.S., and Kenneth K. Wang, M.D. History, Molecular Mechanisms,and Endoscopic Treatment of Barrett‘s Esophagus Gastroenterology.
2010 March ;138(3): 854–869.125. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer.CancerMetastasis Rev 2009;28:177–83.126. Testoni P.A. Medical Indications to Antireflux Surgery in GastroesophagealReflux Disease.// Gastroenterology International. Vol. 10, Suppl.2 p. 32-33, 1997.127.
Theisen J., Nigro J.J., DeMeester T.R., Peters J.H., Gastal O.L., Hagen J.A.,Hashemi M., Bremner C.G. Chronology of the Barrett‗s metaplasia-dysplasiacarcinoma sequence. Dis Esophagus. 2004.128. Timmer M.R., Brankley S.M., et al. Prediction of Response to EndoscopicTherapy of Barrett‘s Dysplasia using Genetic Biomarkers.
Gastrointest Endosc.2014; 80(6): 984–991.129. Tosh D., Slack J.M. How cells change their phenotype. Nat. Rev. Mol. Cell.Biol. 2002; 3(3): 187–194.130. US National Cancer Institute. SEER Stat Fact Sheets: Esophagus; 2010.http://seer.cancer.gov/statfacts/html/esoph.html - survival. Accessed October 5,2010.131. Vallbohmer D, DeMeester SR, Oh DS, et al.
Antireflux surgery normalizescyclooxygenase-2 expression in squamous epithelium of the distal oesophagus.Am J Gastroenterol 2006;101:1458e66.169132. Van Blankenstein M., Looman C.W., Johnston B.J., Caygill C.P. Age andsex distribution of the prevalence of Barrett's esopha¬gus found in a primaryreferral endoscopy center. Am J Gastroenterol 2005; 100:568-576.133. Van Eyken P. Definition of Barrett's oesophagus. // Acta Gastroenterol Belg.2000 Jan-Mar;63(1): 10-2.134. Varghese S., P. Lao-Sirieix, and R.
C. Fitzgerald, ―Identification and clinicalimplementation of biomarkers for Barrett‘s esophagus,‖Gastroenterology, vol.142, no. 3, pp. 435–441, 2012.135. Wang D.H., Souza R.F. Biology of Barrett‘s Esophagus and EsophagealAdenocarcinoma. Gastrointest. Endosc. Clin. N. Am. 2011; 21(1): 25–38.136. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis,surveillance and therapy of Barrett‘s esophagus. Am.
J. Gastroenterol. 2008; 103:788–97.137. Westerterp M, Koppert LB, BuskensС J, etal. Outcome of surgical treatmentfor early adenocarcinoma of the esophagus or gastro-esophageal junction.Virchows Arch 2005;446:497-504.138. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholome K, Timmer J, etal.
Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma usingsingle nucleotide polymorphism arrays. Lab Invest 2009;89:385–97.139. Wolfsen H.C., Ng C.S. Cutaneous consequences of photodynamic therapy //Cutis. - 2002. - Vol. 69.-N2.-P. 140-142.140. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, et al.Hypomethylation of noncoding DNA regions and overexpression of the longnoncodingRNA,AFAP1-AS1,inBarrett'sesophagusandesophagealadenocarcinoma.
Gastroenterology. 2013 Jan 16. [Epub ahead of print].141. Yagi K, Nakamura A, Sekine A. Accuracy of magnifying endoscopy withmethylene blue in the diagnosis of specialized intestinal metaplasia and shortsegment Barrett's esophagus in Japanese patients without Helicobacter pyloriinfection // Gastrointest Endosc. 2003 Aug;58(2):189- 95.170142. Zhai R, Zhao Y, Su L, Cassidy L, Liu G, Christiani DC. Genome-wide DNAmethylation profiling of cell-free serum DNA in esophageal adenocarcinoma andBarrett esophagus. Neoplasia 2012;14:29–33.143.
Zhe Jin, Yulan Cheng, Wen Gu et al. A multicenter, double-blindedvalidation study of methylation biomarkers for progression prediction in Barrett‘sesophagus. Cancer Res. 2009; 69(10): 4112–4115.171.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
